Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Emery

Showing results (81-90 of 140) with videos related to

Pageof 14
Sort By:
AIDS Research and Human Retroviruses|July 13, 2013
Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreportingJohn M Murray, John J Zaunders, Kersten K Koelsch, et al.
Research and Practice in Thrombosis and Haemostasis|October 24, 2018
In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virusKathleen E Brummel-Ziedins, Matthew Gissel, Jacqueline Neuhaus, et al.
The Journal of Infectious Diseases|October 29, 2008
Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunctionPatrick W G Mallon, Rebecca Sedwell, Gary Rogers, et al.
Human Vaccines|October 3, 2006
Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trialsRobert De Rose, Mark T Sullivan, C Jane Dale, et al.
Journal of Virology|January 10, 2014
HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapyJohn M Murray, John J Zaunders, Kristin L McBride, et al.
Neuroradiology|July 10, 2012
Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapyAlan Winston, Chris Duncombe, Patrick C K Li, et al.
AIDS (London, England)|July 26, 2011
The development of an expert system to predict virological response to HIV therapy as part of an online treatment support toolAndrew D Revell, Dechao Wang, Mark A Boyd, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 30, 2014
Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapyHila Haskelberg, Patrick W G Mallon, Jennifer Hoy, et al.
AIDS (London, England)|March 3, 2015
Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levelsWilliam J Hey-Cunningham, John M Murray, Ven Natarajan, et al.
The Journal of Infectious Diseases|April 20, 2005
In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNAPatrick W G Mallon, Patrick Unemori, Rebecca Sedwell, et al.
Pageof 14

Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
AIDS Research and Human Retroviruses|July 13, 2013
Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreportingJohn M Murray, John J Zaunders, Kersten K Koelsch, et al.
Research and Practice in Thrombosis and Haemostasis|October 24, 2018
In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virusKathleen E Brummel-Ziedins, Matthew Gissel, Jacqueline Neuhaus, et al.
The Journal of Infectious Diseases|October 29, 2008
Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunctionPatrick W G Mallon, Rebecca Sedwell, Gary Rogers, et al.
Human Vaccines|October 3, 2006
Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trialsRobert De Rose, Mark T Sullivan, C Jane Dale, et al.
Journal of Virology|January 10, 2014
HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapyJohn M Murray, John J Zaunders, Kristin L McBride, et al.
Neuroradiology|July 10, 2012
Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapyAlan Winston, Chris Duncombe, Patrick C K Li, et al.
AIDS (London, England)|July 26, 2011
The development of an expert system to predict virological response to HIV therapy as part of an online treatment support toolAndrew D Revell, Dechao Wang, Mark A Boyd, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 30, 2014
Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapyHila Haskelberg, Patrick W G Mallon, Jennifer Hoy, et al.
AIDS (London, England)|March 3, 2015
Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levelsWilliam J Hey-Cunningham, John M Murray, Ven Natarajan, et al.
The Journal of Infectious Diseases|April 20, 2005
In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNAPatrick W G Mallon, Patrick Unemori, Rebecca Sedwell, et al.
Pageof 14